CSL Behring to Feature Secondary Immunodeficiency Symposium at the 2018 Meeting of the European Society for Immunodeficiencies (ESID)

ESID platinum sponsor to partner with experts examining causes of secondary immunodeficiency

LISBON, Portugal – 22 October 2018 – Global biotherapeutics leader CSL Behring today announced that it will host a panel of cross-specialty experts at its “Current and Emerging Causes of Secondary Immunodeficiencies” symposium at the ESID meeting this week in Lisbon.  In addition to the symposium, the platinum sponsor will also support six scientific posters, host a “meet the experts” session and encourage exhibit booth attendees to participate in a donation activity to benefit IPOPI, the International Patient Organisation for Primary Immunodeficiencies. 

“Powerful partnerships with patient organisations, healthcare professionals and leading scientific experts fuel innovation at CSL Behring,” says Karen MacPhail, Senior Director, Immunology, CSL Behring.  “We are driven by advancing research and building upon our established portfolio to bring solutions to patients and providers.” 

Thursday’s (25 October) satellite symposium “Current and Emerging Causes of Secondary Immunodeficiencies” (12:20-13:50, Auditorium VI, Centro de Congressos de Lisboa) will be chaired by Stephen Jolles (UK) and include experts Klaus Warnatz (Germany), Troy Torgerson (USA), and Neil Robertson (UK).  The symposium will examine iatrogenic causes of secondary antibody deficiencies, persistent antibody deficiency after bone marrow transplantation and CAR-T cell therapy, B-cell depletion in neuroinflammatory disease and a roundtable discussion.   There will also be an opportunity to meet these experts for a Q&A after the symposium at CSL Behring’s exhibit booth later in the day (13:35-16:05, Exhibit Hall Booth #3).   While at the exhibit booth, visitors will also have an opportunity to support a donation to IPOPI and will also be able to watch videos via and augmented reality display that will bring patient stories to life.

CSL Behring supported posters include:

  • #283: Manual push immunoglobulin G replacement therapy in adult and paediatric patients affected by Primary immunodeficiency disease: Protocol of a prospective study
  • # 284: Bi-weekly 20%-subcutaneous immunoglobulins (Hizentra®) infusion in patients with primary immunodeficiencies: Treatment exposure an infusion parameters during the Italian IBIS Study
  • # 297: Bi-weekly 20%-subcutaneous immunoglobulin (Hizentra®) infusion in patients with common variable immunodeficiency.Primary endpoints in the CVID subcohort of the IBIS Study
  • #302: An Open-Label Multicenter Study of the Tolerability of Higher than Current Infusion Parameters of the 20% Subcutaneous Immunoglobulin IgPro20 in Primary Immunodeficiency: The HiLo Study
  • #303: Serum IG Trough Levels Following Switch from IV to Subcutaneous Immunoglobulin Replacement Therapy at Equal Dose: Data from Europe and Japanese Trials
  • #309: Subcutaneous Immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: A randomised trial

About Hizentra®

Hizentra® (human normal immunoglobulin, SCIg), the first 20 percent subcutaneous immunoglobulin developed for subcutaneous use, is registered in over 51 countries and approved to treat certain immune deficiencies and chronic inflammatory demyelinating polyneuropathy (CIDP). Hizentra®, the world's most prescribed subcutaneous immunoglobulin, has a proven track record of safety, efficacy, and tolerability and has over 4.8 million exposures worldwide since 2010.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries. For inspiring stories about the promise of biotechnology, visit Vita  CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.

# # #

Media Contact

Jennifer Purdue
Office: +1 610 878 4802
Mobile: +1 610 306 9355
Email: jennifer.purdue@cslbehring.com